DMC Biotechnologies, Inc. filed a Form D with the Securities and Exchange Commission on 2025-12-30.
DMC Biotechnologies, Inc. filed a Form D notice of an exempt securities offering with the SEC on December 30, 2025. The filing reports $1.41M sold. Its industry group is Biotechnology. It names Jim Flatt (Executive Officer, Director), Rob van der Meij (Director), Josko Bobanovic (Director) (SEC Form D, December 30, 2025).
Sell to companies like DMC Biotechnologies, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-12-30 · the record
Pitching, partnering or investing alongside them? See who really runs and owns DMC Biotechnologies, Inc.
Free to see. No signup.
More on the people and the money behind DMC Biotechnologies, Inc., from the filings we hold.
Biotechnology raises filed within 90 days of this one, largest first.
Get an email when DMC Biotechnologies, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when DMC Biotechnologies, Inc. raises, hires or launches. No email unless you switch it on.
Watch DMC Biotechnologies, Inc. →Get the full cited report on DMC Biotechnologies, Inc.
What the filing shows about DMC Biotechnologies, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on DMC Biotechnologies, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for DMC Biotechnologies, Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on DMC Biotechnologies, Inc. See pricing
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 759 filings in Biotechnology, totalled by week. The dot is this raise, $1.41M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Jim Flatt is named as Executive Officer and Director on the Form D that DMC Biotechnologies, Inc. filed with the SEC on 30 December 2025, one of 8 people that filing names.
Rob van der Meij is named as Director on the Form D that DMC Biotechnologies, Inc. filed with the SEC on 30 December 2025, one of 8 people that filing names.
Josko Bobanovic is named as Director on the Form D that DMC Biotechnologies, Inc. filed with the SEC on 30 December 2025, one of 8 people that filing names.
Doug Cameron is named as Director on the Form D that DMC Biotechnologies, Inc. filed with the SEC on 30 December 2025, one of 8 people that filing names.
Alastair Cooper is named as Director on the Form D that DMC Biotechnologies, Inc. filed with the SEC on 30 December 2025, one of 8 people that filing names.
Matthew Lipscomb is named as Director on the Form D that DMC Biotechnologies, Inc. filed with the SEC on 30 December 2025, one of 8 people that filing names.
K'Lynne Johnson is named as Director on the Form D that DMC Biotechnologies, Inc. filed with the SEC on 30 December 2025, one of 8 people that filing names.
Josh Yelen is named as Executive Officer on the Form D that DMC Biotechnologies, Inc. filed with the SEC on 30 December 2025, one of 8 people that filing names.
8 people named on the filing — 2 holding an executive role and 6 as directors only.
Named as of the 2025-12-30 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about DMC Biotechnologies, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on DMC Biotechnologies, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on DMC Biotechnologies, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist DMC Biotechnologies, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind DMC Biotechnologies, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for DMC Biotechnologies, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Denver and Boulder
https://mentionfox.com/funding/dmc-biotechnologies-inc-form-d-25000002